Cencora Inc (COR)
Industry Medical Distribution
This stock can be held in an Investment ISA and an Investment Account
Sell
$338.79
Buy
$347.25
$1.50 (+0.44%)
Prices updated at 12 Dec 2025, 23:46 EST
| Prices minimum 15 mins delay
Prices in USD
AmerisourceBergen Corp is a pharmaceutical services company. It provides drug distribution and related healthcare services and solutions to pharmacy, physician, and manufacturer customers based in the United States and Canada.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2024 | 2025 |
|---|---|---|
| 293,959m | 321,333m | |
| 9,910m | 11,479m | |
| 3,157m | 3,934m | |
| 1.07 | 1.22 | |
| 1,509m | 1,554m | |
| 3,371m | 3,747m | |
| Sales, General and administrative | 5,661m | 6,494m |
| Interest expenses | 249m | 420m |
| Provision for income taxes | 485m | 691m |
| Operating expenses | 6,753m | 7,545m |
| Income before taxes | 2,004m | 2,258m |
| Net income available to common shareholders | 1,509m | 1,554m |
| 7.11 | 8.02 | |
| Net interest income | -157m | -292m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | 7.05 | 7.96 |
| Free cash flow per share | 14.9663 | 16.4288 |
| Book value/share | 3.3322 | 7.7736 |
| Debt equity ratio | 5.9011 | 5.001918 |
Balance sheet
Year | 2024 | 2025 |
|---|---|---|
| Current assets | 47,718m | 52,239m |
| Current liabilities | 54,277m | 57,821m |
| Total capital | 4,458m | 9,051m |
| Total debt | 4,388m | 7,661m |
| Total equity | 646m | 1,508m |
| Total non current liabilities | - | - |
| Loans | 3,812m | 7,543m |
| Total assets | 67,102m | 76,590m |
| Total liabilities | - | - |
| Cash and cash equivalents | 3,133m | 4,356m |
| Common stock | 195m | 194m |
Cash flow
Year | 2024 | 2025 |
|---|---|---|
| Cash at beginning of period | 2,753m | 3,298m |
| Cash dividends paid | -416m | -437m |
| 2,998m | 3,207m | |
| Investments (gains) losses | -618m | -4,977m |
| 3,298m | 4,395m | |
| Net income | - | - |
| 3,485m | 3,875m | |
| -487m | -668m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
